請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/2385完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 胡文聰 | |
| dc.contributor.author | Chun-Ting Kuo | en |
| dc.contributor.author | 郭俊廷 | zh_TW |
| dc.date.accessioned | 2021-05-13T06:39:39Z | - |
| dc.date.available | 2019-08-30 | |
| dc.date.available | 2021-05-13T06:39:39Z | - |
| dc.date.copyright | 2017-08-30 | |
| dc.date.issued | 2017 | |
| dc.date.submitted | 2017-08-08 | |
| dc.identifier.citation | [1] DeSantis, C. E., et al. (2016). 'Breast cancer statistics, 2015: Convergence of incidence rates between black and white women.' CA Cancer J Clin 66(1): 31-42.
[2] Nole, F., et al. (2008). 'Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications.' Ann Oncol 19(5): 891-897. [3] Nagrath, S., et al. (2007). 'Isolation of rare circulating tumour cells in cancer patients by microchip technology.' Nature 450(7173): 1235-1239. [4] Bertoli, G., et al. (2015). 'MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer.' Theranostics 5(10): 1122-1143. [5] Tomaskovic-Crook, E., et al. (2009). 'Epithelial to mesenchymal transition and breast cancer.' Breast Cancer Res 11(6): 213. [6] Lamouille, S. and R. Derynck (2007). 'Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway.' Journal of Cell Biology 178(3): 437-451. [7] Lamouille, S., et al. (2012). 'TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion.' J Cell Sci 125(Pt 5): 1259-1273. [8] Chao, S. K., et al. (2011). 'Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence.' Oncotarget 2(1-2): 89-98. [9] Feng, Z. and A. J. Levine (2010). 'The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein.' Trends Cell Biol 20(7): 427-434. [10] Polunovsky, Vitaly A., Houghton, Peter J. (2010). ' mTOR Pathway and mTOR Inhibitors in Cancer Therapy. ' Cancer Drug Discovery and Development. [11] Weigelt, B., et al. (2011). 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.' Oncogene 30(29): 3222-3233. [12] Holder, A. M., et al. (2015). 'Epithelial to mesenchymal transition is associated with rapamycin resistance.' Oncotarget 6(23): 19500-19513. [13] Noh, W. C., et al. (2004). 'Determinants of rapamycin sensitivity in breast cancer cells.' Clin Cancer Res 10(3): 1013-1023. [14] Hurvitz, S. A., et al. (2015). 'In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.' Breast Cancer Res Treat 149(3): 669-680. [15] Kang, S. A., et al. (2013). 'mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin.' Science 341(6144): 1236566. [16] Treilleux, I., et al. (2015). 'Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.' Ann Oncol 26(1): 120-125. [17] Faes, S., et al. (2017). 'Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity.' Oxidative Medicine and Cellular Longevity. [18] Mohseni, M. and B. H. Park (2010). 'PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.' Journal of Clinical Investigation 120(8): 2655-2658. [19] Choo, A. Y., et al. (2008). 'Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.' Proc Natl Acad Sci U S A 105(45): 17414-17419. [20] Gerdes, M. J., et al. (2013). 'Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue.' Proc Natl Acad Sci U S A 110(29): 11982-11987. [21] Leroy, C., et al. (2016). 'Activation of IGF1R/p110beta/AKT/mTOR confers resistance to alpha-specific PI3K inhibition.' Breast Cancer Res 18(1): 41. [22] Karthik, G. M., et al. (2015). 'mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.' Cancer Lett 367(1): 76-87. [23] Satheesha, S., et al. (2011). 'Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.' Mol Cancer 10: 19. [24] Riquelme, I., et al. (2016). 'The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.' Pathol Oncol Res 22(4): 797-805. [25] Rodrik-Outmezguine, V. S., et al. (2016). 'Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.' Nature 534(7606): 272-276. [26] Xu, J., et al. (2016). 'Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.' J Clin Invest 126(9): 3526-3540. [27] Koo, J., et al. (2015). 'GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.' Oncotarget 6(11): 8974-8987. [28] McCubrey, J. A., et al. (2014). 'GSK-3 as potential target for therapeutic intervention in cancer.' Oncotarget 5(10): 2881-2911. [29] Chen, I. C., et al. (2016). 'Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer.' Scientific Reports 6. [30] Li, J., et al. (2014). 'Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion.' J Exp Clin Cancer Res 33: 70. [31] Liu, W., et al. (2017). 'Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance.' Oncotarget. [32] Yoon, S. O. and P. P. Roux (2013). 'Rapamycin resistance: mTORC1 substrates hold some of the answers.' Curr Biol 23(19): R880-883. [33] Saran, U., et al. (2015). 'Cellular and molecular effects of the mTOR inhibitor everolimus.' Clin Sci (Lond) 129(10): 895-914. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/2385 | - |
| dc.description.abstract | 在許多癌症腫瘤中，PI3K/AKT/mTOR路徑常被激勵活化並且掌控癌細胞的主要功能。PI3K/AKT/mTOR路徑的下游分子，磷酸化的4EBP1蛋白及磷酸化的S6K1激酶更在細胞的生化功能裡扮演重要的角色。除此之外，mTOR標靶治療更是在乳癌病人對於賀爾蒙治療或化學治療產生抗藥性時進行治療。而讓mTOR中的專一性鍵結失效來達到調降 PI3K/AKT/mTOR路徑的活化程度的癌伏妥錠(Everolimus)則為mTOR標靶治療中常見的藥物。但在某些mTOR標靶治療病人當中，癌伏妥錠卻沒有產生其應達到的治療效果。本論文研究係以免疫螢光方式對於Hs578T, MCF7, BT474, MDA-MB-231, 乳癌細胞株及ABC-82T及ABC-16TX1 PDCC細胞株進行mTOR抑制劑癌伏妥錠(Everolimus)之敏感度測定。先以標準MTT測試及細胞生長率測試判別其細胞株之藥物敏感度，而後則是利用磷酸化4EBP1 Thr37/46蛋白抗體及磷酸化S6K1 Ser424激酶抗體對細胞株進行免疫螢光亮值測定以和測出的敏感度加以比較。研究結果顯示利用免疫螢光之分析方法的確可指出其乳癌細胞株對於癌伏妥錠(Everolimus)之敏感度。單獨的磷酸化4EBP1 Thr37/46蛋白抗體及磷酸化S6K1 Ser424激酶抗體之螢光表現可將乳癌細胞株及PDCC細胞株進行分群，磷酸化4EBP1 Thr37/46及磷酸化S6K1 Ser424兩者綜合之螢光亮值則可代表其藥物敏感度程度。當細胞對癌伏妥錠具有抗藥性潛力時，磷酸化4EBP1 Thr37/46及磷酸化S6K1 Ser424亦會產生動態變化，並且由實驗結果得知mTOR藥物的抗藥性並不是只對於AKT/mTOR路徑有專一性，而是與其它特定蛋白如LKB1或其他路徑如MAPK/ERK路徑有關。 | zh_TW |
| dc.description.abstract | In many solid tumors, the PI3K/AKT/mTOR pathway is activated and is believed to play major roles in a range of cellular functions. Downstream of this pathway, pho-4EBP1 and pho-S6K1 perform critical role in controlling biological processes. In breast cancer, when patients start to exhibit resistance with hormonal therapy or chemotherapy, mTOR inhibitor, for example Everolimus, is often considered, which can deregulate the PI3K/AKT/mTOR pathway by allosteric binding the catalytic site of mTORC1. But in some mTOR-targeted therapy cases, Everolimus does not exhibit the desired efficacy. This work assesses the use of immunofluorescence analysis to predict the efficacy of the mTOR inhibitor Everolimus using breast cancer cell lines- Hs578T, MCF7, BT474, MDA-MB-231-and patient-derived cell culture (PDCC)-ABC-82T, and ABC-16TX1.These cells provided predictive information on the sensitivity of Everolimus using cell viability and MTT assays based on immunofluorescence intensities of pho-4EBP1 Thr37/46 and pho-S6K1 Ser424. Results show that the immunofluorescence analyses can be used to indicate the efficacy of mTOR inhibitor Everolimus on cells tested. Independently,pho-4EBP1 Thr37/46 and pho-S6K1 Ser424 immunofluorescence expression can classify into different groups based on their intensities for cell lines and PDCC. The combined immunofluorescence intensity of pho-4EBP1 Thr37/46 and pho-S6K1 Ser424 is representative of the efficacy of Everolimus. Results also suggest that dynamitic change for pho-4EBP1 and pho-S6K1 occur when cells have resistance characteristic of Everolimus. Further, mTOR resistance is not only consequence of AKT/mTOR but also by LKB1 or MAPK/ERK pathway.Furthermore, LKB1 and pho-GSK3β may also be potential markers to predict the efficacy of Everolimus therapy. | en |
| dc.description.provenance | Made available in DSpace on 2021-05-13T06:39:39Z (GMT). No. of bitstreams: 1 ntu-106-R02543036-1.pdf: 1579793 bytes, checksum: 2f974b6afd7610c6ad9792f7439b2070 (MD5) Previous issue date: 2017 | en |
| dc.description.tableofcontents | 致謝 …………………………………………………………………………………………………… i
中文摘要…………………………………………………………………………………………………...ii Abstract…………………………………………………………………………………………………….iii Contents………………………………………………………………………………………………….....v List of Figures………………………………………………………………………………………….....vii List of Tables……………………………………………………………………………………………...ix Chapter 1. Introduction 1 1.1 Breast cancer and epithelial-mesenchymal transition…………………………………………...1 1.2 The PI3K/AKT/mTOR pathway…………………………………………………………………3 1.2.1 Growth factors actuate the PI3K/AKT/mTOR pathway………………………..............3 1.2.2 EIF4E-phosphorylated-4EBP1 protein and phosphorylated -S6K1 protein……………4 1.3 Motivation of this work………………………………………………………………………….6 1.3.1 Targeted therapy and mTOR inhibitory drug sensitivity in breast cancer……………...6 1.3.2 Clinical analysis method for phosphorylated protein—comparison between immunofluorescence, q-PCR , immunohistochemistry and western blot………………7 1.4 The goal of this thesis…………………………………………………………………………….8 Chapter 2. Materials and Methods 9 2.1 The experimental structure………………………………………………………………………..9 2.2 Cell culture, cell lines, and patient-derived cell culture (PDCC)………………………………..9 2.3 Reagents………………………………………………………………………………………....11 2.4 Cell viability rate assay………………………………………………………………………….12 2.5 MTT and IC50 assays……………………………………………………..…………………….12 2.6 Immunofluorescence staining…………………………………………………………………...13 2.7 Western blots…………………………………………………………………………………….14 2.8 Statistical analysis……………………………………………………………………………….15 Chapter 3 Results and Discussion 16 3.1 Immunofluorescence marker for Everolimus resistance in cell lines and PDCC……………….........16 3.1.1 Gene mutation and drug sensitivity……………………………………………............16 3.1.2 Cell viability rate and IC50 value of cell lines and PDCC………………………..…...17 3.1.3 Immunofluorescence expression of mTOR markers and Everolimus sensitivity……..20 3.2 Pho-4EBP1 and pho-S6K1 do not have high specificity for AKT/mTOR……………………...28 3.3 Combined IF expression of pho-4EBP1 and pho-S6K1 before and after adding Everolimus……………………………………………………………………………………..33 3.4 Epithelial-mesenchymal transition state and Everolimus sensitivity…………………………...35 3.5 The arrangement of IF marker in rare cancer cells detection……………………………….......36 Chapter 4 Conclusions 38 References 39 | |
| dc.language.iso | en | |
| dc.subject | 癌伏妥錠 | zh_TW |
| dc.subject | mTOR路徑 | zh_TW |
| dc.subject | 磷酸化S6K1 | zh_TW |
| dc.subject | 磷酸化4EBP1 | zh_TW |
| dc.subject | mTOR抗藥性 | zh_TW |
| dc.subject | MTT測試 | zh_TW |
| dc.subject | MTT assay | en |
| dc.subject | pho-4EBP1 | en |
| dc.subject | pho-S6K1 | en |
| dc.subject | mTOR resistance | en |
| dc.subject | mTOR | en |
| dc.subject | Everolimus | en |
| dc.title | 利用免疫螢光進行乳癌mTOR 途徑藥物癌伏妥錠(Everolimus)敏感度評估研究 | zh_TW |
| dc.title | Use of immunofluorescence to assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 105-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 盧彥伸,林季宏 | |
| dc.subject.keyword | mTOR路徑,癌伏妥錠,磷酸化4EBP1,磷酸化S6K1,mTOR抗藥性,MTT測試, | zh_TW |
| dc.subject.keyword | mTOR,Everolimus,pho-4EBP1,pho-S6K1,mTOR resistance,MTT assay, | en |
| dc.relation.page | 42 | |
| dc.identifier.doi | 10.6342/NTU201701484 | |
| dc.rights.note | 同意授權(全球公開) | |
| dc.date.accepted | 2017-08-08 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 應用力學研究所 | zh_TW |
| 顯示於系所單位： | 應用力學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-106-1.pdf | 1.54 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。